Loading...
Market
Will Genentech report any adverse events related to Susvimo eye implant within three months of reintroduction?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Genentech press releases and FDA adverse event reporting system
Story
Genentech, Roche Unit, Reintroduces Susvimo Eye Implant After Recall
Jul 8, 2024, 07:24 PM
Genentech, a unit of Roche Group, has announced the reintroduction of its eye implant, Susvimo, in the United States. The implant is designed for people with wet age-related macular degeneration (AMD), a blinding eye disease. The re-launch follows the end of a voluntary recall that took place two years ago. Susvimo, which was recalled, is a refillable implant, and it will be available to patients in the coming weeks. The announcement was made on Monday.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No reports • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
Acknowledge risk and issue warning • 25%
Deny risk and continue marketing • 25%
Initiate further studies • 25%
Discontinue affected products • 25%
Yes • 50%
No • 50%
